1-Phenyl-1-cyclopentanecarbonitrile

We are 1-Phenyl-1-cyclopentanecarbonitrile CAS:77-57-6 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:  1-Phenyl-1-cyclopentanecarbonitrile
CAS.NO:77-57-6
Molecular Formula:C12H13N
Molecular Weight:171.23800

Synonyms:
1-phenylcyclopentane-1-carbonitrile

Physical and Chemical Properties:
Density: 1.03
Boiling point: 135-140 ° C (10 mmHg)
Flash point: 113.5ºC
Refractive index: 1.5325-1.5345

Specification:
Appearance:yellow to white solid
Purity:≥98.0%
Moisture Content: 0.25%
Impurity: 0.3%

Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.
Application:An important raw material and intermediate used in Organic Synthesis,Pharmaceuticals.

Related News: You will find the name and amount of the active ingredient contained in the medicine on the package of OTC (over-the-counter) drugs.4-(4-aminophenoxy)-N-methylpyridine-2-carboxamide Zhejiang Huahai Pharmaceutical: It is a leading company in domestic APIs, especially in the field of cardiovascular drugs.3-[2-(4-chlorophenoxy)phenyl]-1-methylpyrrolidine-2,4-dione CAS:912356-07-1 The fine and functional chemicals sector provides new growth drivers.3-BROMO-2-FLUORO-4-YODOPIRIDINA CAS:884494-52-4 An effective treatment for Alzheimer’s, which is estimated in 60%-70% of around 50 million dementia cases worldwide, could become one of the best-selling drugs globally.These mathematical dosing algorithms were developed in the Damiano Lab at Boston University and refined based on results from home-use clinical trials in adults and children with T1D. Beta Bionics is a Certified B Corporation? whose founders — in addition to Ed Damiano — include other parents of children with type 1 diabetes and people with type 1 diabetes. Beta Bionics is committed to acting in the best interests of the diabetes community and to profoundly disrupting the diabetes medical device industry by bringing the iLet to market as expeditiously and responsibly as possible.